Unknown

Dataset Information

0

Protective activity of mRNA vaccines against ancestral and variant SARS-CoV-2 strains.

ABSTRACT: Although mRNA vaccines prevent COVID-19, variants jeopardize their efficacy as immunity wanes. Here, we assessed the immunogenicity and protective activity of historical (mRNA-1273, designed for Wuhan-1 spike) or modified (mRNA-1273.351, designed for B.1.351 spike) preclinical Moderna mRNA vaccines in 129S2 and K18-hACE2 mice. Immunization with high or low dose formulations of mRNA vaccines induced neutralizing antibodies in serum against ancestral SARS-CoV-2 and several variants, although levels were lower particularly against the B.1.617.2 (Delta) virus. Protection against weight loss and lung pathology was observed with all high-dose vaccines against all viruses. Nonetheless, low-dose formulations of the vaccines, which produced lower magnitude antibody and T cell responses, and serve as a possible model for waning immunity, showed breakthrough lung infection and pneumonia with B.1.617.2. Thus, as levels of immunity induced by mRNA vaccines decline, breakthrough infection and disease likely will occur with some SARS-CoV-2 variants, suggesting a need for additional booster regimens.

SUBMITTER: Ying B 

PROVIDER: S-EPMC8404887 | biostudies-literature | 2021 Aug

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Although mRNA vaccines prevent COVID-19, variants jeopardize their efficacy as immunity wanes. Here, we assessed the immunogenicity and protective activity of historical (mRNA-1273, designed for Wuhan-1 spike) or modified (mRNA-1273.351, designed for B.1.351 spike) preclinical Moderna mRNA vaccines in 129S2 and K18-hACE2 mice. Immunization with high or low dose formulations of mRNA vaccines induced neutralizing antibodies in serum against ancestral SARS-CoV-2 and several variants, although level  ...[more]

Similar Datasets

Unknown Protective activity of mRNA vaccines against ancestral and variant SARS-CoV-2 strains.
| S-EPMC8817234 | biostudies-literature
Unknown mRNA-1273 and BNT162b2 mRNA vaccines have reduced neutralizing activity against the SARS-CoV-2 omicron variant.
| S-EPMC8784612 | biostudies-literature
Unknown Omicron-specific mRNA vaccine induced cross-protective immunity against ancestral SARS-CoV-2 infection with low neutralizing antibodies.
| S-EPMC9877661 | biostudies-literature
Unknown mRNA-1273 and Ad26.COV2.S vaccines protect against the B.1.621 variant of SARS-CoV-2.
| S-EPMC9011903 | biostudies-literature
Unknown Development of Bivalent mRNA Vaccines against SARS-CoV-2 Variants.
| S-EPMC9693459 | biostudies-literature
Unknown COVID-19 mRNA booster vaccines elicit strong protection against SARS-CoV-2 Omicron variant in patients with cancer.
| S-EPMC8716174 | biostudies-literature
Unknown Bivalent SARS-CoV-2 mRNA vaccines increase breadth of neutralization and protect against the BA.5 Omicron variant.
| S-EPMC9580377 | biostudies-literature
Unknown Bacteria-enabled oral delivery of a replicon-based mRNA vaccine candidate protects against ancestral and delta variant SARS-CoV-2.
| S-EPMC8810265 | biostudies-literature
Unknown mRNA booster immunization elicits potent neutralizing serum activity against the SARS-CoV-2 Omicron variant.
| S-EPMC8767537 | biostudies-literature
Unknown SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral spike vaccines.
| S-EPMC7934674 | biostudies-literature